Sunshine Lake Pharma Co., Ltd. (HKG:6887)
Hong Kong · Delayed Price · Currency is HKD 37.28
+0.78 (2.14%)
At close: Jun 1, 2026
Sunshine Lake Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 272.44 | -207.43 | 1,993 | 76.6 | -587.65 |
Depreciation & Amortization | 461.93 | 418.04 | 391.27 | 377.36 | 259.82 |
Loss (Gain) From Sale of Assets | 3.08 | -18.14 | 0.53 | 0.82 | 19.07 |
Asset Writedown & Restructuring Costs | 67.8 | 68.31 | 485.39 | 288.84 | 25.98 |
Loss (Gain) From Sale of Investments | 16.7 | -6.32 | -4.39 | -522.7 | -19.24 |
Loss (Gain) on Equity Investments | -0.25 | -0.6 | -0.22 | - | - |
Stock-Based Compensation | 258.67 | 266.55 | 45.14 | - | - |
Other Operating Activities | 238.15 | 274.89 | 165.31 | 1,084 | 136.21 |
Change in Accounts Receivable | -121.13 | 1.44 | -1,418 | -530.59 | -216.1 |
Change in Inventory | -87.82 | -208.84 | -94.02 | -35.33 | 98.57 |
Change in Accounts Payable | 45.6 | -87.35 | 109.49 | 961.31 | -379.18 |
Operating Cash Flow | 1,155 | 500.53 | 1,673 | 1,700 | -662.51 |
Operating Cash Flow Growth | 130.79% | -70.09% | -1.57% | - | - |
Capital Expenditures | -836.04 | -1,062 | -343.72 | -570.07 | -356.29 |
Sale of Property, Plant & Equipment | 1.83 | 61.28 | - | 0.95 | 0.03 |
Sale (Purchase) of Intangibles | -84.73 | -163.3 | -251.36 | -283 | -223.4 |
Investment in Securities | -13.58 | -11.07 | 2,579 | -290 | - |
Other Investing Activities | 449.06 | 1,205 | -1,430 | 21.95 | 140.55 |
Investing Cash Flow | -483.45 | 29.79 | 554.57 | -1,120 | -439.11 |
Long-Term Debt Issued | 2,675 | 3,480 | 2,164 | 517.94 | 444.96 |
Long-Term Debt Repaid | -2,503 | -4,306 | -3,454 | -1,146 | -157.68 |
Total Debt Repaid | -2,503 | -4,306 | -3,454 | -1,146 | -157.68 |
Net Debt Issued (Repaid) | 172.73 | -825.69 | -1,290 | -628.22 | 287.28 |
Repurchase of Common Stock | -19.18 | - | - | - | - |
Common Dividends Paid | -584.43 | - | - | - | - |
Other Financing Activities | -234.79 | -144.98 | -186.63 | -158.8 | -99.8 |
Financing Cash Flow | -665.67 | -970.67 | -1,477 | -787.03 | 187.48 |
Foreign Exchange Rate Adjustments | -0.08 | 0.99 | -0.01 | -0.3 | 0.29 |
Net Cash Flow | 5.99 | -439.35 | 750.87 | -207.58 | -913.85 |
Free Cash Flow | 319.14 | -561.37 | 1,329 | 1,130 | -1,019 |
Free Cash Flow Growth | - | - | 17.67% | - | - |
Free Cash Flow Margin | 6.63% | -13.97% | 21.12% | 30.17% | -111.49% |
Free Cash Flow Per Share | 0.64 | -1.27 | 5.73 | 4.87 | -4.39 |
Cash Interest Paid | 226.73 | 111.68 | 138.32 | 112.74 | 99.8 |
Cash Income Tax Paid | 120.33 | 247.64 | 230.49 | 255.43 | -18.62 |
Levered Free Cash Flow | 650.05 | 982.84 | 1,067 | -2,703 | -616.5 |
Unlevered Free Cash Flow | 793.93 | 1,133 | 1,209 | -2,527 | -464.12 |
Change in Working Capital | -163.35 | -294.76 | -1,402 | 395.39 | -496.71 |